DRPevader: Ex vivo-diagnosis and prognosis of early diabetic retinopathy

A novel ex vivo method for immediate early diagnosis and prognosis of proliferative diabetic retinopathy (DRP) is provided with DRPevader.

DRPevader is based on the analysis of expression and activity of very few genes which can simply be determined using whole blood or a blood component. Therefore, DRPevader is the diagnostic link between the alteration of leukocyte gene expression, the activity of specific serum-markers, and proliferative DRP.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

New anti-cancer agent works without oxygen

Why tumors shrink but don’t disappear. “As tumors grow very quickly, consume a lot of oxygen and their vascular growth can’t necessarily keep pace, they often contain areas that are…

First blueprint of the human spliceosome revealed

Researchers detail the inner workings of the most complex and intricate molecular machine in human biology. Researchers at the Centre for Genomic Regulation (CRG) in Barcelona have created the first…

A paper-aluminum combo for strong, sustainable packaging

Takeout containers get your favorite noodles from the restaurant to your dining table (or couch) without incident, but they are nearly impossible to recycle if they are made from foil-lined…